FeesSafety
Pluang+

Cohen & Steers fund offers 8.83% yield but faces price volatility and discount risks amid rate hikes.

Market News
10 Sep 2026
Seeking Alpha
View Source
Neutral
Cohen & Steers fund offers 8.83% yield but faces price volatility and discount risks amid rate hikes.

The Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund provides a high yield of 8.83%, well above the preferred stock index average. However, its share price has been mostly flat over three years and recently declined due to sensitivity to interest rates and leverage-related volatility. The fund covers its distributions through net investment income and realized gains, but investors should watch its large unrealized losses that could affect sustainability. Trading at a 10.16% discount to net asset value, deeper than its five-year average, the fund faces challenges from ongoing rate hikes and inflation, which may limit capital growth potential.

More News

Dayton T. Brown opens new Huntsville Test & Qualification Center to boost aerospace and defense testing.

Dayton T. Brown opens new Huntsville Test & Qualification Center to boost aerospace and defense testing.

Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...

Market News
Bullish
1 hour ago
60% of CCOs say communications functions lag behind their leadership roles, needing better systems and resources.

60% of CCOs say communications functions lag behind their leadership roles, needing better systems and resources.

A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandat...

Others
Neutral
1 hour ago
Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development

Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development

More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...

Market News
Bullish
1 hour ago
Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.

Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.

Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...

Market News
Bullish
1 hour ago
Nokia beats Q3 earnings and revenue estimates with strong AI and cloud sales growth.

Nokia beats Q3 earnings and revenue estimates with strong AI and cloud sales growth.

Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App